Nkarta
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1150 Veterans Blvd, South San Francisco,...Phone Number
(925) 407-1049Website
www.nkartatx.comRevenue
-Stock Symbol
NKTXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
1
1
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, which are engineered to enhance tumor targeting and improve persistence for sustained activity in the body.Explore more
Nkarta Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nkarta your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Nkarta has new funding data
Earning: See what the market has to say on Nkarta recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Nkarta launches new products
Check out if Nkarta is spiking on competitors!
Nkarta, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Nkarta has recently received funding, and reach out quickly before it becomes old news!
Click to see if Nkarta had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Nkarta
Recommended Actions
Find VP level buyers at Nkarta
Find more new buyers
Compare Similar Companies to Nkarta
Compare insights from companies similar to Nkarta, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Nkarta is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Nkarta is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Nkarta.
Nkarta financials insights
Gather financial insights about Nkarta, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$11M
2019
Series B
$114M
Nkarta Tech Stack
A closer look at the technologies used by Nkarta
Most Recent Scoops
Open Position
Person-Based
Earnings, Clinical Operations, Finance
Event
Person-Based
Events, Podcast
Person-Based
Lawsuits, Legal Affairs, Regulations
Person-Based
Lawsuits, Legal Affairs, Finance, Regulations, Risk
Nkarta News & Media
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its selection for three scientific presentations at ACR Convergence 2026 being held November 6-11 in Orlando.Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026.Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside at the H.C. Wainwright Cell Therapy Virtual Conference.Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Nkarta
Sign Up For FreeTo access detailed company insights
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient... Read More
